Microbot Medical Inc. (NASDAQ:MBOT) Receives $7.50 Consensus Price Target from Brokerages

Microbot Medical Inc. (NASDAQ:MBOT) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $7.50.

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm initiated coverage on Microbot Medical in a research note on Wednesday, December 3rd. They set a “buy” rating and a $5.50 price target for the company. Finally, B. Riley Financial initiated coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They set a “buy” rating for the company.

Institutional Trading of Microbot Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Microbot Medical by 14.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after acquiring an additional 292,923 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of Microbot Medical by 1.8% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock worth $2,960,000 after purchasing an additional 26,000 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Microbot Medical in the 3rd quarter worth $4,435,000. Heights Capital Management Inc. bought a new position in Microbot Medical in the 3rd quarter worth $2,693,000. Finally, Geode Capital Management LLC raised its holdings in Microbot Medical by 54.4% in the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after purchasing an additional 268,609 shares during the period. 16.30% of the stock is owned by hedge funds and other institutional investors.

Microbot Medical Trading Up 13.1%

Shares of MBOT opened at $2.85 on Friday. The firm has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $2.52. The firm has a market cap of $191.41 million, a PE ratio of -6.33 and a beta of 1.22. Microbot Medical has a 1-year low of $1.35 and a 1-year high of $4.67.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.